Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta‐analysis
暂无分享,去创建一个
S. Barni | F. Petrelli | A. Coinu | M. Ghilardi | M. Cabiddu | V. Lonati | K. Borgonovo
[1] V. Ho,et al. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Robert,et al. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. , 2016, Journal of the American Academy of Dermatology.
[3] H. Kennecke,et al. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer , 2016, Supportive Care in Cancer.
[4] Kazuhiro Yoshida,et al. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients. , 2015, Anticancer research.
[5] M. Benasso,et al. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. , 2015, Critical reviews in oncology/hematology.
[6] O. Arrieta,et al. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. , 2015, Lung cancer.
[7] M. Lacouture,et al. Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics. , 2015 .
[8] Hideaki Takahashi,et al. Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study , 2015, American Journal of Clinical Dermatology.
[9] K. Hatanaka,et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. , 2015, Future oncology.
[10] F. de Marinis,et al. management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. , 2014, Clinical lung cancer.
[11] C. Sonetto,et al. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. , 2014, Clinical colorectal cancer.
[12] J. Fischer,et al. Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation , 2013, Science Translational Medicine.
[13] P. Galle,et al. Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective , 2013, Journal of Cancer Research and Clinical Oncology.
[14] H. Tomková,et al. Phytomenadione pre‐treatment in EGFR inhibitor‐induced folliculitis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[15] S. Barni,et al. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials , 2013, Targeted Oncology.
[16] S. Barni,et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. , 2012, Lung cancer.
[17] O. Chosidow,et al. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature , 2012, The British journal of dermatology.
[18] M. Ychou,et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. , 2012, The oncologist.
[19] A. Rademaker,et al. Higher severity grade of erlotinib‐induced rash is associated with lower skin phototype , 2011, Clinical and experimental dermatology.
[20] P. Novotny,et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB) , 2011, Supportive Care in Cancer.
[21] M. Lacouture,et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities , 2011, Supportive Care in Cancer.
[22] E. Maiello,et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. , 2011, The oncologist.
[23] M. Lacouture,et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Sargent,et al. Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 , 2008, Oncology.
[25] A. Halpern,et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Lacouture. Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.
[27] G. Girolomoni,et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. , 2003, The American journal of pathology.
[28] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[29] Jong Hoon Kim,et al. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. , 2013, European journal of dermatology : EJD.
[30] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[31] B. Thiers. Tetracycline to Prevent Epidermal Growth Factor Receptor Inhibitor-induced Skin Rashes: Results of a Placebo-controlled Trial From the North Central Cancer Treatment Group (N03CB) , 2009 .
[32] K. Ang,et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.